Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time.

@article{Asnani2018BetaBlockersFP,
  title={Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time.},
  author={Aarti Asnani},
  journal={Journal of the American College of Cardiology},
  year={2018},
  volume={71 20},
  pages={2291-2292}
}
SEE PAGE 2281 C ancer survival rates have improved significantly over the past few decades. In 2016, there were 15.5 million cancer survivors in the United States—a number that is expected to increase to 20 million over the next 10 years (1). Despite the increasing use of targeted antitumor agents, many of these patients will have received traditional cytotoxic chemotherapies such as the anthracyclines, which continue to serve as the backbone of treatment regimens for breast cancer, leukemia… CONTINUE READING